These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30623340)

  • 1. Is FGFR2 a Suitable Target to Treat Scirrhous-Type Gastric Cancer?
    Yasui W
    Ann Surg Oncol; 2019 Apr; 26(4):926-927. PubMed ID: 30623340
    [No Abstract]   [Full Text] [Related]  

  • 2. Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14.
    Okuno T; Yashiro M; Masuda G; Togano S; Kuroda K; Miki Y; Hirakawa K; Ohsawa M; Wanibuchi H; Ohira M
    Ann Surg Oncol; 2019 Apr; 26(4):1093-1102. PubMed ID: 30652228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.
    Hong L; Han Y; Liu J; Brain L
    Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):759-65. PubMed ID: 24134151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.
    Yashiro M; Shinto O; Nakamura K; Tendo M; Matsuoka T; Matsuzaki T; Kaizaki R; Miwa A; Hirakawa K
    Int J Cancer; 2010 Feb; 126(4):1004-16. PubMed ID: 19621385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
    Nakamura K; Yashiro M; Matsuoka T; Tendo M; Shimizu T; Miwa A; Hirakawa K
    Gastroenterology; 2006 Nov; 131(5):1530-41. PubMed ID: 17101326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanisms responsible for the progression of scirrhous gastric cancer].
    Yashiro M; Ohira M; Muguruma K; Shinto O; Hirakawa K
    Nihon Rinsho; 2012 Oct; 70(10):1812-6. PubMed ID: 23198567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
    Kawajiri H; Yashiro M; Shinto O; Nakamura K; Tendo M; Takemura S; Node M; Hamashima Y; Kajimoto T; Sawada T; Ohira M; Hirakawa K
    Clin Cancer Res; 2008 May; 14(9):2850-60. PubMed ID: 18451253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-β signaling.
    Hasegawa T; Yashiro M; Nishii T; Matsuoka J; Fuyuhiro Y; Morisaki T; Fukuoka T; Shimizu K; Shimizu T; Miwa A; Hirakawa K
    Int J Cancer; 2014 Apr; 134(8):1785-95. PubMed ID: 24155219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line.
    Tamaki R; Kanai-Mori A; Morishige Y; Koike A; Yanagihara K; Amano F
    Oncol Rep; 2017 Apr; 37(4):2366-2374. PubMed ID: 28260018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving outcome for scirrhous gastric cancer.
    Hartgrink HH
    Gastric Cancer; 2009; 12(1):3-5. PubMed ID: 19390926
    [No Abstract]   [Full Text] [Related]  

  • 12. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of nonresectable scirrhous type gastric cancer treated by hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
    Ishikawa T; Mita Y; Kobayashi M; Tashiro K; Tashiro S; Matsuki H
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1137-40. PubMed ID: 11525032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent results of therapy for scirrhous gastric cancer.
    Ikeguchi M; Miyake T; Matsunaga T; Yamamoto M; Fukumoto Y; Yamada Y; Fukuda K; Saito H; Tatebe S; Tsujitani S
    Surg Today; 2009; 39(4):290-4. PubMed ID: 19319634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Endocrine therapy of scirrhous carcinoma of the stomach].
    Kojima O; Takahashi T
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2526-31. PubMed ID: 3017229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic-assisted intraperitoneal chemotherapy for patients with scirrhous gastric cancer.
    Ikeguchi M; Matsumoto S; Yoshioka S; Murakami D; Kanaji S; Ohro S; Yamaguchi K; Saito H; Tatebe S; Kondo A; Tsujitani S; Kaibara N
    Chemotherapy; 2005 Mar; 51(1):15-20. PubMed ID: 15722628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of nonresectable scirrhous type gastric cancer successfully treated by low-dose cisplatin (CDDP), 5-fluorouracil (5-FU) and pirarubicin (THP)].
    Gochi A; Murashima N; Gotoh K; Matsuno T; Matsuoka J; Tanaka N; Orita K
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):905-8. PubMed ID: 10897219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of individual sensitivity of gastric cancer to 5-fluorouracil by tumor tissue respiratory and glycolytic indices].
    Shiian DN
    Vopr Onkol; 1975; 21(2):34-40. PubMed ID: 165632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
    Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
    Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer.
    Murahashi K; Yashiro M; Inoue T; Nishimura S; Matsuoka T; Sawada T; Sowa M; Hirakawa-Ys Chung K
    Int J Oncol; 1998 Dec; 13(6):1235-40. PubMed ID: 9824637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.